Pulse Biosciences, Inc.

NasdaqCM PLSE

Pulse Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024

Pulse Biosciences, Inc. Cash and Short-Term Investments is NA for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Pulse Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 50.39 M, a -27.15% change year over year.
Pulse Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 69.16 M, a 64.71% change year over year.
Pulse Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 41.99 M, a 41.93% change year over year.
Pulse Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 29.59 M, a -14.24% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: PLSE

Pulse Biosciences, Inc.

CEO	Mr. Robert W. Duggan
IPO Date	May 18, 2016
Location	United States
Headquarters	3957 Point Eden Way
Employees	56
Sector	Health Care
Industries Biotechnology Energy Storage & Batteries Pharmaceuticals

Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Key trends

Past 5 years